| Characteristic . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| No. of participants | 295 | 125 | 76 | 76 | 18 |
| Demographic factors | |||||
| Male sex | 134 (45) | 37 (30) | 29 (38) | 50 (66) | 18 (100) |
| Age, y, median (range) | 35 (18–71) | 35 (18–64) | 34 (18–64) | 36 (19–58) | 44 (24–71) |
| Clinical factors | |||||
| BMI <18.5 kg/m2 | 38 (13) | 13 (10) | 9 (12) | 13 (17) | 3 (17) |
| CD4 countb, cells/μL, median (IQR) | 305 (183–501) | 411 (277–598) | … | 161 (48–273) | … |
| Detectable HIV plasma RNAb | 134 (68) | 84 (68) | … | 50 (68) | … |
| HIV plasma RNAb, log10 copies/mL, median (IQR) | 4.6 (4.2–5.1) | 4.5 (4.2–5.0) | … | 5.0 (4.3–5.5) | … |
| KS any oral lesionc | 25 (27) | … | … | 25 (33) | 0 (0) |
| KS tumor stage T1c | 82 (87) | … | … | 66 (87) | 16 (89) |
| Received ART prior to session 1d | 36 (18) | 0 (0) | … | 35 (46) | … |
| Received ART concurrently with session 1d | 48 (24) | 8 (6) | … | 40 (53) | … |
| Received chemotherapy prior to session 1d | 8 (9) | … | … | 8 (11) | 0 (0) |
| Received chemotherapy concurrently with session 1d | 29 (31) | … | … | 24 (32) | 5 (28) |
| Behavioral factors | |||||
| Alcohol use | 111 (38) | 47 (38) | 34 (45) | 23 (30) | 7 (39) |
| Smoking status | |||||
| Current | 26 (9) | 8 (6) | 11 (14) | 5 (7) | 2 (11) |
| Past | 40 (14) | 17 (14) | 5 (7) | 17 (22) | 1 (6) |
| Never | 229 (78) | 100 (80) | 60 (79) | 54 (71) | 15 (83) |
| Lifetime sex partners, No., median (IQR) | 5 (3–10) | 5 (3–10) | 4 (2–6) | 6 (5–13) | 5 (4–8) |
| Any sex partners in past 3 mo | 160 (55) | 67 (54) | 53 (71) | 27 (36) | 13 (72) |
| Condom use last 3 mo | |||||
| All the time | 55 (34) | 31 (46) | 12 (23) | 12 (44) | 0 (0) |
| More than half the time | 21 (13) | 16 (24) | 4 (8) | 1 (4) | 0 (0) |
| Less than half the time | 18 (11) | 3 (4) | 9 (17) | 5 (19) | 1 (8) |
| Never | 66 (41) | 17 (25) | 28 (53) | 9 (33) | 12 (92) |
| Characteristic . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| No. of participants | 295 | 125 | 76 | 76 | 18 |
| Demographic factors | |||||
| Male sex | 134 (45) | 37 (30) | 29 (38) | 50 (66) | 18 (100) |
| Age, y, median (range) | 35 (18–71) | 35 (18–64) | 34 (18–64) | 36 (19–58) | 44 (24–71) |
| Clinical factors | |||||
| BMI <18.5 kg/m2 | 38 (13) | 13 (10) | 9 (12) | 13 (17) | 3 (17) |
| CD4 countb, cells/μL, median (IQR) | 305 (183–501) | 411 (277–598) | … | 161 (48–273) | … |
| Detectable HIV plasma RNAb | 134 (68) | 84 (68) | … | 50 (68) | … |
| HIV plasma RNAb, log10 copies/mL, median (IQR) | 4.6 (4.2–5.1) | 4.5 (4.2–5.0) | … | 5.0 (4.3–5.5) | … |
| KS any oral lesionc | 25 (27) | … | … | 25 (33) | 0 (0) |
| KS tumor stage T1c | 82 (87) | … | … | 66 (87) | 16 (89) |
| Received ART prior to session 1d | 36 (18) | 0 (0) | … | 35 (46) | … |
| Received ART concurrently with session 1d | 48 (24) | 8 (6) | … | 40 (53) | … |
| Received chemotherapy prior to session 1d | 8 (9) | … | … | 8 (11) | 0 (0) |
| Received chemotherapy concurrently with session 1d | 29 (31) | … | … | 24 (32) | 5 (28) |
| Behavioral factors | |||||
| Alcohol use | 111 (38) | 47 (38) | 34 (45) | 23 (30) | 7 (39) |
| Smoking status | |||||
| Current | 26 (9) | 8 (6) | 11 (14) | 5 (7) | 2 (11) |
| Past | 40 (14) | 17 (14) | 5 (7) | 17 (22) | 1 (6) |
| Never | 229 (78) | 100 (80) | 60 (79) | 54 (71) | 15 (83) |
| Lifetime sex partners, No., median (IQR) | 5 (3–10) | 5 (3–10) | 4 (2–6) | 6 (5–13) | 5 (4–8) |
| Any sex partners in past 3 mo | 160 (55) | 67 (54) | 53 (71) | 27 (36) | 13 (72) |
| Condom use last 3 mo | |||||
| All the time | 55 (34) | 31 (46) | 12 (23) | 12 (44) | 0 (0) |
| More than half the time | 21 (13) | 16 (24) | 4 (8) | 1 (4) | 0 (0) |
| Less than half the time | 18 (11) | 3 (4) | 9 (17) | 5 (19) | 1 (8) |
| Never | 66 (41) | 17 (25) | 28 (53) | 9 (33) | 12 (92) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV–, human immunodeficiency virus seronegative; HIV+, human immunodeficiency virus seropositive; IQR, interquartile range; KS–, without Kaposi sarcoma; KS+, with Kaposi sarcoma.
aNumbers may not add to totals due to missing data.
bAmong HIV-positive participants only. HIV plasma RNA log10 copies/mL only summarized among samples with detectable HIV plasma RNA. Maximum value (750 000 copies/mL) used for samples above the maximum limit of detection.
cAmong participants with KS only.
dSession 1 refers to the first period of 28 days of daily home oral swab collection.
| Characteristic . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| No. of participants | 295 | 125 | 76 | 76 | 18 |
| Demographic factors | |||||
| Male sex | 134 (45) | 37 (30) | 29 (38) | 50 (66) | 18 (100) |
| Age, y, median (range) | 35 (18–71) | 35 (18–64) | 34 (18–64) | 36 (19–58) | 44 (24–71) |
| Clinical factors | |||||
| BMI <18.5 kg/m2 | 38 (13) | 13 (10) | 9 (12) | 13 (17) | 3 (17) |
| CD4 countb, cells/μL, median (IQR) | 305 (183–501) | 411 (277–598) | … | 161 (48–273) | … |
| Detectable HIV plasma RNAb | 134 (68) | 84 (68) | … | 50 (68) | … |
| HIV plasma RNAb, log10 copies/mL, median (IQR) | 4.6 (4.2–5.1) | 4.5 (4.2–5.0) | … | 5.0 (4.3–5.5) | … |
| KS any oral lesionc | 25 (27) | … | … | 25 (33) | 0 (0) |
| KS tumor stage T1c | 82 (87) | … | … | 66 (87) | 16 (89) |
| Received ART prior to session 1d | 36 (18) | 0 (0) | … | 35 (46) | … |
| Received ART concurrently with session 1d | 48 (24) | 8 (6) | … | 40 (53) | … |
| Received chemotherapy prior to session 1d | 8 (9) | … | … | 8 (11) | 0 (0) |
| Received chemotherapy concurrently with session 1d | 29 (31) | … | … | 24 (32) | 5 (28) |
| Behavioral factors | |||||
| Alcohol use | 111 (38) | 47 (38) | 34 (45) | 23 (30) | 7 (39) |
| Smoking status | |||||
| Current | 26 (9) | 8 (6) | 11 (14) | 5 (7) | 2 (11) |
| Past | 40 (14) | 17 (14) | 5 (7) | 17 (22) | 1 (6) |
| Never | 229 (78) | 100 (80) | 60 (79) | 54 (71) | 15 (83) |
| Lifetime sex partners, No., median (IQR) | 5 (3–10) | 5 (3–10) | 4 (2–6) | 6 (5–13) | 5 (4–8) |
| Any sex partners in past 3 mo | 160 (55) | 67 (54) | 53 (71) | 27 (36) | 13 (72) |
| Condom use last 3 mo | |||||
| All the time | 55 (34) | 31 (46) | 12 (23) | 12 (44) | 0 (0) |
| More than half the time | 21 (13) | 16 (24) | 4 (8) | 1 (4) | 0 (0) |
| Less than half the time | 18 (11) | 3 (4) | 9 (17) | 5 (19) | 1 (8) |
| Never | 66 (41) | 17 (25) | 28 (53) | 9 (33) | 12 (92) |
| Characteristic . | Total . | HIV+/KS− . | HIV−/KS− . | HIV+/KS+ . | HIV−/KS+ . |
|---|---|---|---|---|---|
| No. of participants | 295 | 125 | 76 | 76 | 18 |
| Demographic factors | |||||
| Male sex | 134 (45) | 37 (30) | 29 (38) | 50 (66) | 18 (100) |
| Age, y, median (range) | 35 (18–71) | 35 (18–64) | 34 (18–64) | 36 (19–58) | 44 (24–71) |
| Clinical factors | |||||
| BMI <18.5 kg/m2 | 38 (13) | 13 (10) | 9 (12) | 13 (17) | 3 (17) |
| CD4 countb, cells/μL, median (IQR) | 305 (183–501) | 411 (277–598) | … | 161 (48–273) | … |
| Detectable HIV plasma RNAb | 134 (68) | 84 (68) | … | 50 (68) | … |
| HIV plasma RNAb, log10 copies/mL, median (IQR) | 4.6 (4.2–5.1) | 4.5 (4.2–5.0) | … | 5.0 (4.3–5.5) | … |
| KS any oral lesionc | 25 (27) | … | … | 25 (33) | 0 (0) |
| KS tumor stage T1c | 82 (87) | … | … | 66 (87) | 16 (89) |
| Received ART prior to session 1d | 36 (18) | 0 (0) | … | 35 (46) | … |
| Received ART concurrently with session 1d | 48 (24) | 8 (6) | … | 40 (53) | … |
| Received chemotherapy prior to session 1d | 8 (9) | … | … | 8 (11) | 0 (0) |
| Received chemotherapy concurrently with session 1d | 29 (31) | … | … | 24 (32) | 5 (28) |
| Behavioral factors | |||||
| Alcohol use | 111 (38) | 47 (38) | 34 (45) | 23 (30) | 7 (39) |
| Smoking status | |||||
| Current | 26 (9) | 8 (6) | 11 (14) | 5 (7) | 2 (11) |
| Past | 40 (14) | 17 (14) | 5 (7) | 17 (22) | 1 (6) |
| Never | 229 (78) | 100 (80) | 60 (79) | 54 (71) | 15 (83) |
| Lifetime sex partners, No., median (IQR) | 5 (3–10) | 5 (3–10) | 4 (2–6) | 6 (5–13) | 5 (4–8) |
| Any sex partners in past 3 mo | 160 (55) | 67 (54) | 53 (71) | 27 (36) | 13 (72) |
| Condom use last 3 mo | |||||
| All the time | 55 (34) | 31 (46) | 12 (23) | 12 (44) | 0 (0) |
| More than half the time | 21 (13) | 16 (24) | 4 (8) | 1 (4) | 0 (0) |
| Less than half the time | 18 (11) | 3 (4) | 9 (17) | 5 (19) | 1 (8) |
| Never | 66 (41) | 17 (25) | 28 (53) | 9 (33) | 12 (92) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV–, human immunodeficiency virus seronegative; HIV+, human immunodeficiency virus seropositive; IQR, interquartile range; KS–, without Kaposi sarcoma; KS+, with Kaposi sarcoma.
aNumbers may not add to totals due to missing data.
bAmong HIV-positive participants only. HIV plasma RNA log10 copies/mL only summarized among samples with detectable HIV plasma RNA. Maximum value (750 000 copies/mL) used for samples above the maximum limit of detection.
cAmong participants with KS only.
dSession 1 refers to the first period of 28 days of daily home oral swab collection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
